Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Patritumab Deruxtecan (HER3-DXd) in Patients with EGFR Mutation-Positive Advanced NSCLC

February 9th 2024

Dr. Gadgeel reviews the HERTHENA-Lung01 trial results of the HER3 targeting antibody drug conjugate patritumab deruxtecan in EGFR-positive non-small cell lung cancer.

Continued ADC Development in NSCLC Necessitates Improved Knowledge of Mechanisms and Biomarker Optimization

February 7th 2024

Identifying biomarkers and the mechanism of action of antibody-drug conjugates may optimize benefits with these agents in non–small cell lung cancer.

Neoadjuvant vs Perioperative Immune Checkpoint Blockade in Resectable NSCLC: How Do We Choose?

February 7th 2024

Survival outcomes following curative resection in resectable NSCLC have been poor and, until recently, the main tool oncologists had at their disposal was neoadjuvant or adjuvant chemotherapy.

EGFR TKI–Based Combinations May Revolutionize Frontline EGFR+ NSCLC Management

February 7th 2024

Balazs Halmos, MD, discusses the FLAURA2 and MARIPOSA trials of EGFR TKIs plus chemotherapy in EGFR-mutated non–small cell lung cancer.

Regulatory Filings Accepted for Perioperative Nivolumab Plus Chemotherapy in NSCLC

February 7th 2024

The FDA and EMA have accepted applications seeking the approval of neoadjuvant nivolumab/chemotherapy followed by surgery and adjuvant nivolumab in NSCLC.

2023 Data Readouts Enable New Treatment Avenues in Oncogene-Driven NSCLC

February 7th 2024

Edgardo S. Santos Castillero, MD, FACP, spotlights some impactful trials in lung cancer that were discussed in 2023, including the phase 3 MARIPOSA-2 trial, and more.

Dr Olazagasti on a Case-Based Discussion of ALK-Mutated NSCLC Treatment

February 6th 2024

Coral Olazagasti, MD, discusses her participation in a case-based discussion at the 21st Annual Winter Lung Cancer Conference®.

Dr Rosner on Personalizing Approaches to Perioperative Therapy in NSCLC

February 6th 2024

Samuel Rosner, MD, discusses ongoing efforts to individualize the use of perioperative/neoadjuvant therapy in early-stage NSCLC.

EGFR-Targeted TKIs Continue to Have Outsized Impact in NSCLC

February 6th 2024

Thomas J. Lynch Jr, MD, details how treatments are evolving for patients with EGFR-mutated advanced non–small cell lung cancer.

Diving Into Adjuvant Approaches in Early-Stage Resectable NSCLC: PD-L1 Expression and Genomic Considerations

February 6th 2024

Corey J. Langer, MD, FACP, discusses findings from the IMpower010 and KEYNOTE-091 studies, which examined immunotherapy in NSCLC.

Sacituzumab Govitecan + Pembrolizumab in First-Line Metastatic NSCLC

February 6th 2024

Dr. Shirish Gadgeel discusses recent EVOKE-2 trial results showing promising response rates with sacituzumab govitecan combined with pembrolizumab for metastatic non-small cell lung cancer.

The Importance of Lung Cancer Screening in Individuals Exposed to the World Trade Center Disaster

February 6th 2024

Investigators evaluated risk factor–based guidelines and risk model–based strategies for lung cancer screening in World Trade Center–exposed responders.

Santos Breaks Down Key Updates From 2023 in the Management of EGFR-Mutant NSCLC

February 6th 2024

Edgardo S. Santos Castillero, MD, FACP, expands on outcomes from pivotal phase 3 trials such as ADAURA and FLAURA2 in patients with EGFR-mutant NSCLC.

FDA Grants Fast Track Designation to UV1 Cancer Vaccine for Unresectable/Metastatic Mesothelioma

February 5th 2024

The UV1 cancer vaccine received fast track designation for use in combination with ipilimumab and nivolumab for patients with unresectable malignant pleural mesothelioma.

Dr Halmos on Treatment Strategies For EGFR-Mutant NSCLC

February 4th 2024

Balazs Halmos, MD, discusses treatment strategies for patients with EGFR-mutant non–small cell lung cancer.

Dr Curran on Developing Strategies for Stage III NSCLC Management

February 4th 2024

Wally Curran, MD, discusses current and developing treatment strategies for patients with stage III unresectable non–small cell lung cancer.

Dr Levy on Unanswered Questions Regarding the Mechanism of Action of ADCs in NSCLC

February 3rd 2024

Benjamin Levy, MD, discusses the mechanism of action of antibody-drug conjugates in patients with non–small cell lung cancer.

Dr Leal on the Development of DLL3-Targeted Agents in SCLC

February 3rd 2024

Ticiana Leal, MD, discusses the variety of DLL3-targeted agents in development for patients with small cell lung cancer and neuroendocrine tumors.

Dr Pellini on the Development of Increasingly Sensitive ctDNA Assays in NSCLC

February 3rd 2024

Bruna Pellini, MD, discusses the importance of developing circulating tumor DNA assays with increased sensitivity.

Dr Rodriguez on the Use of HER2-Directed Therapies in NSCLC

February 3rd 2024

Estelamari Rodriguez, MD, MPH, discusses adverse effects associated with HER2-directed antibody-drug conjugates in non–small cell lung cancer.